{"id":"azd9150","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"5-15%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By binding to the mRNA of the MYC oncogene, AZD9150 prevents the translation of MYC protein, which is often overexpressed in various cancers. This reduction in MYC protein levels can inhibit tumor growth and proliferation.","oneSentence":"AZD9150 is an antisense oligonucleotide that targets the RNA of the MYC oncogene, leading to reduced expression of MYC protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:30:29.390Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors, including lymphoma and multiple myeloma"}]},"trialDetails":[{"nctId":"NCT03819465","phase":"PHASE1","title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-27","conditions":"Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":175},{"nctId":"NCT02499328","phase":"PHASE1, PHASE2","title":"Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-06","conditions":"Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck","enrollment":340},{"nctId":"NCT05814666","phase":"PHASE2","title":"Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC","status":"TERMINATED","sponsor":"Flamingo Therapeutics NV","startDate":"2023-05-30","conditions":"HNSCC","enrollment":69},{"nctId":"NCT02546661","phase":"PHASE1","title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2016-12-28","conditions":"Muscle Invasive Bladder Cancer","enrollment":117},{"nctId":"NCT05986240","phase":"PHASE1","title":"Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-05-08","conditions":"AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT02983578","phase":"PHASE2","title":"Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-03-02","conditions":"Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma","enrollment":39},{"nctId":"NCT03421353","phase":"PHASE1","title":"AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-02-07","conditions":"Advanced Solid Tumours","enrollment":76},{"nctId":"NCT03527147","phase":"PHASE1","title":"Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2018-06-19","conditions":"NHL, DLBCL, Non-hodgkin's Lymphoma","enrollment":30},{"nctId":"NCT03794544","phase":"PHASE2","title":"Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2019-03-08","conditions":"Resectable, Early-stage, NSCLC","enrollment":84},{"nctId":"NCT03394144","phase":"PHASE1","title":"Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-01-30","conditions":"Advanced Solid Malignancies","enrollment":11},{"nctId":"NCT02549651","phase":"PHASE1","title":"MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2016-07-13","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":32},{"nctId":"NCT02417753","phase":"PHASE2","title":"AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-04-03","conditions":"Ovarian Cancer, Ovarian Neoplasms, Ascites","enrollment":1},{"nctId":"NCT01839604","phase":"PHASE1","title":"A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-05","conditions":"Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic","enrollment":58}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"DRUG-INDUCED LIVER INJURY"},{"count":3,"reaction":"PLEURAL EFFUSION"},{"count":2,"reaction":"LOWER GASTROINTESTINAL HAEMORRHAGE"},{"count":2,"reaction":"MOUTH HAEMORRHAGE"},{"count":2,"reaction":"THROMBOCYTOPENIA"},{"count":2,"reaction":"TRANSAMINASES INCREASED"},{"count":1,"reaction":"ADRENAL INSUFFICIENCY"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["STAT3 inhibitor","ISIS 481464"],"phase":"phase_2","status":"active","brandName":"AZD9150","genericName":"AZD9150","companyName":"Acerta Pharma BV","companyId":"acerta-pharma-bv","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD9150 is an antisense oligonucleotide that targets the RNA of the MYC oncogene, leading to reduced expression of MYC protein. Used for Advanced solid tumors, including lymphoma and multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}